857 related articles for article (PubMed ID: 16453090)
1. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.
Bruckert E; Hayem G; Dejager S; Yau C; Bégaud B
Cardiovasc Drugs Ther; 2005 Dec; 19(6):403-14. PubMed ID: 16453090
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of statin therapy due to muscular side effects: a survey in real life.
Rosenbaum D; Dallongeville J; Sabouret P; Bruckert E
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):871-5. PubMed ID: 22748604
[TBL] [Abstract][Full Text] [Related]
3. An insight into statin use and its association with muscular side effects in clinical practice.
Farcas A; Bucsa C; Leucuta D; Mogosan C; Bojita M; Dumitrascu D
Rom J Intern Med; 2015; 53(2):153-60. PubMed ID: 26402985
[TBL] [Abstract][Full Text] [Related]
4. Managing the underestimated risk of statin-associated myopathy.
Rallidis LS; Fountoulaki K; Anastasiou-Nana M
Int J Cardiol; 2012 Sep; 159(3):169-76. PubMed ID: 21813193
[TBL] [Abstract][Full Text] [Related]
5. Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries.
Chaipichit N; Krska J; Pratipanawatr T; Jarernsiripornkul N
Int J Clin Pharm; 2015 Apr; 37(2):355-64. PubMed ID: 25630895
[TBL] [Abstract][Full Text] [Related]
6. Statin use and its association with musculoskeletal symptoms--a cross-sectional study in primary care settings.
Mosshammer D; Lorenz G; Meznaric S; Schwarz J; Muche R; Mörike K
Fam Pract; 2009 Apr; 26(2):88-95. PubMed ID: 19233960
[TBL] [Abstract][Full Text] [Related]
7. Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients.
Berta E; Harangi M; Zsíros N; Nagy EV; Paragh G; Bodor M
Pharmazie; 2014 Jun; 69(6):420-3. PubMed ID: 24974574
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
10. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia.
Harris LJ; Thapa R; Brown M; Pabbathi S; Childress RD; Heimberg M; Braden R; Elam MB
J Clin Lipidol; 2011; 5(4):299-307. PubMed ID: 21784376
[TBL] [Abstract][Full Text] [Related]
11. Statin intolerance.
Ahmad Z
Am J Cardiol; 2014 May; 113(10):1765-71. PubMed ID: 24792743
[TBL] [Abstract][Full Text] [Related]
12. Statin-related muscle complaints: an underestimated risk.
Corsini A
Cardiovasc Drugs Ther; 2005 Dec; 19(6):379-81. PubMed ID: 16453086
[No Abstract] [Full Text] [Related]
13. The risk for significant creatine kinase elevation with statins.
Stolcpart RS; Olson KL; Delate T; Rasmussen J; Rehring TF; Merenich JA
Am J Cardiovasc Drugs; 2010; 10(3):187-92. PubMed ID: 20524720
[TBL] [Abstract][Full Text] [Related]
14. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.
Chuengsamarn S; Rattanamongkoulgul S; Suwanwalaikorn S; Wattanasirichaigoon S; Kaufman L
Bone; 2010 Apr; 46(4):1011-5. PubMed ID: 20045497
[TBL] [Abstract][Full Text] [Related]
15. [Muscle problems due to statins: underestimated].
Janssen SP; Smulders YM; Gerdes VE; Visseren FL
Ned Tijdschr Geneeskd; 2010; 154():A1684. PubMed ID: 21435278
[TBL] [Abstract][Full Text] [Related]
16. [Statins and their pleiotropic effects].
Galus R; Zandecki Ł; Jóźwiak J; Włodarski K
Pol Merkur Lekarski; 2008 Jun; 24(144):545-8. PubMed ID: 18702340
[TBL] [Abstract][Full Text] [Related]
17. Statin induced myotoxicity.
Sathasivam S
Eur J Intern Med; 2012 Jun; 23(4):317-24. PubMed ID: 22560377
[TBL] [Abstract][Full Text] [Related]
18. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.
Fung EC; Crook MA
Cardiovasc Ther; 2012 Oct; 30(5):e212-8. PubMed ID: 21884002
[TBL] [Abstract][Full Text] [Related]
19. Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries.
Rosenson RS; Gandra SR; McKendrick J; Dent R; Wieffer H; Cheng LI; Catapano AL; Oh P; Kees Hovingh G; Stroes ES
Cardiovasc Drugs Ther; 2017 Apr; 31(2):187-195. PubMed ID: 28466399
[TBL] [Abstract][Full Text] [Related]
20. Managing statin-induced muscle toxicity in a lipid clinic.
Blaier O; Lishner M; Elis A
J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
